No Heading
Purpose.
The aim of this study was to investigate the effect of hepatic or renal insufficiency on the pharmacokinetics of paclitaxel in rats.
Methods.
Rats were treated with carbon tetrachloride (CCl4; 0.5 ml/kg) to induce hepatic failure or were subjected to 5/6 nephrectomy (5/6 Nx) to induce renal failure. Paclitaxel (3 mg/kg) was administered intravenously or intraportally. Testosterone 6β-hydroxylase activity, which is a marker of CYP3A activity, was measured in rat liver microsomes from CCl4-treated or 5/6 Nx rats.
Results.
After paclitaxel was administered intravenously, total body clearance was significantly reduced by 73% and 34% relative to each control value in CCl4-treated and 5/6 Nx rats, respectively (control, 1.82 ± 0.42 vs. CCl4-treated, 0.49 ± 0.11; sham, 1.54 ± 0.07 vs. 5/6 Nx, 1.01 ± 0.12 L h−1 kg−1; mean ± SE, n = 5 to 6). Testosterone 6β-hydroxylase activity was reduced by 92% and 59% relative to each control value in rat liver microsomes from CCl4-treated and 5/6 Nx rats, respectively. After the intraportal administration of paclitaxel, apparent clearance was reduced by 85% relative to control value in rats with hepatic failure, while that in rats with renal failure was the same as the reduction in systemic clearance.
Conclusions.
These results suggested that not only hepatic failure but also renal failure could modify the pharmacokinetics of paclitaxel in vivo.
Similar content being viewed by others
Abbreviations
- AUC:
-
area under the plasma concentration-time curve
- HPLC:
-
high-performance liquid chromatography
- 5/6 Nx:
-
5/6 nephrectomy
- Km:
-
Michaelis-Menten constant
- Vmax:
-
maximum velocity
References
1. E. K. Rowinsky and R. C. Donehower. Paclitaxel (Taxol). N. Engl. J. Med. 332:1004–1014 (1995).
2. D. S. Sonnichsen, Q. Liu, E. G. Schuetz, J. D. Schuetz, A. Pappo, and M. V. Relling. Variability in human cytochrome P450 paclitaxel metabolism. J. Pharmcol. Exp. Ther. 275:566–575 (1995).
3. D. S. Sonnichsen and M. V. Relling. Clinical pharmacokinetics of paclitaxel. Clin. Pharmacokinet. 27:256–269 (1994).
4. L. Gianni, C. M. Kearns, A. Giani, G. Capri, L. Viganó, A.Locatelli, G. Bonadonna, and M. J. Egorin. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/ pharmacodynamic relationships in humans. J. Clin. Oncol. 13: 180–190 (1995).
5. T. Ohtsu, Y. Sasaki, T. Tamura, Y. Miyata, H. Nakanomyo, Y. Nishiwaki, and N. Saijo. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion. Clin. Cancer Res. 1:599–606 (1995).
6. M. T. Huizing, G. Giaccone, L. J. C. van Warmerdam, H. Rosing, P. J. M. Bakker, J. B. Vermorken, P. E. Postmus, N. van Zandwijk, M. G. J. Koolen, W. W. ten Bokkel-Huinink, W. J. F. van der Vijg, F. J. Bierhorst, A. Lai, O. Dalesio, H. M. Pinedo, C. H. N. Veenhof, and J. H. Beijnen. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. J. Clin. Oncol. 15:317– 329 (1997).
7. V. Rodighiero. Effects of liver disease on pharmacokinetics. An update. Clin. Pharmacokinet. 37:399–431 (1999).
8. M.-C. Bastien, F. Leblond, V. Pichette, and J.-P. Villeneuve. Differential alteration of cytochrome P450 isozymes in two experimental models of cirrhosis. Can. J. Physiol. Pharmacol. 78:912– 919 (2000).
9. V. R. N. Panday, M. T. Huizing, P. H. B. Willemse, A. De-Graeff, W. W. ten Bokkel-Huinink, J. B. Vermorken, and J. H. Beijnen. Hepatic metabolism of paclitaxel and its impact in patients with altered hepatic function. Semin. Oncol. 24:34–38 (1997).
10. R. Bruno, R. Olivares, J. Berille, P. Chaikin, N. Vivier, L. Hammershaimb, G. R. Rhodes, and J. R. Rigas. α-1-Acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel. Clin. Cancer Res. 9:1077–1082 (2003).
11. T. P. Gibson. Influence of renal disease on pharmacokinetics. In W. E. Evans, L. J. Schentag, and W. J. Jusko (eds.), Applied Pharmacokinetics, 2nd ed, Applied Therapeutics, Washington, DC, 1986, pp. 83–115
12. F. A. Leblond, L. Giroux, J.-P. Villeneuve, and V. Pichette. Decreased in vivo metabolism of drugs in chronic renal failure. Drug Metab. Dispos. 28:1317–1320 (2000).
13. T. C. Dowling, A. E. Briglia, J. C. Fink, D. S. Hanes, P. D. Light, L. Stackiewicz, C. S. Karyekar, N. D. Eddington, M. R. Weir, and W. L. Henrich. Characterization of hepatic cytochrome P4503A activity in patients with end-stage renal disease. Clin. Pharmacol. Ther. 73:427–434 (2003).
14. S.-S. Hong, S.-J. Chung, and C.-K. Shim. Functional impairment of sinusoidal membrane transport of organic cations in rats with CCl4-induced hepatic failure. Pharm. Res. 17:833–838 (2000).
15. L. Ji, S. Masuda, H. Saito, and K. Inui. Down-regulation of rat organic cation transporter rOCT2 by 5/6 nephrectomy. Kidney Int. 62:514–524 (2002).
16. M. Sugiura, K. Iwasaki, H. Noguchi, and R. Kato. Evidence for the involvement of cytochrome P-450 in tiaramide N-oxide reduction. Life Sci. 15:1433–1442 (1974).
17. R. W. Wang, D. J. Newton, T. D. Scheri, and A. Y. H. Lu. Human cytochrome P450 3A4-catalyzed testosterone 6β-hydroxylation and erythromycin N-demethylation. Drug Metab. Dispos. 25:502– 507 (1997).
18. T. Iwahori, T. Matsuura, H. Maehashi, K. Sugo, M. Saito, M. Hosokawa, K. Chiba, T. Masaki, H. Aizaki, K. Ohkawa, and T. Suzuki. CYP3A4 inducible model for in vitro analysis of human drug metabolism using a bioartificial liver. Hepatology 37:665– 673 (2003).
19. T. A. Willey, E. J. Bekos, R. C. Gaver, G. F. Duncan, L. K. Tay, J. H. Beijnen, and R. H. Farmen. High-performance liquid chromatographic procedure for the quantitative determination of paclitaxel (Taxol®) in human plasma. J. Chromatogr. 621:231–238 (1993).
20. J.-S. Choi. Pharmacokinetics of paclitaxel in rabbits with carbon tetrachloride-induced hepatic failure. Arch. Pharm. Res. 25:937– 977 (2002).
21. H. Okabe, I. Yano, Y. Hashimoto, H. Saito, and K. Inui. Evaluation of increased bioavailability of tacrolimus in rats with experimental renal dysfunction. J. Pharm. Pharmacol. 54:65–70 (2002).
22. C. D. Anderson, J. Wang, G. N. Kumar, J. M. Mcmillan, U. K. Walle, and T. Walle. Dexamethasone induction of taxol metabolism in the rat. Drug Metab. Dispos. 23:1286–1290 (1995).
23. H. Okabe, M. Hasunuma, and Y. Hashimoto. The hepatic and intestinal metabolic activities of P450 in rats with surgery- and drug-induced renal dysfunction. Pharm. Res. 20:1591–1594 (2003).
24. A. Sparreboom, J. van Asperen, U. Mayer, A. H. Schinkel, J. W. Smit, D. K. F. Meijer, P. Borst, W. J. Nooijen, J. H. Beijnen, and O. van Tellingen. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. USA 94:2031–2035 (1997).
25. M. R. Feng, J. Loo, and J. Wright. Disposition of the antipsychotic agent CI-1007 in rats, monkeys, dogs, and human cytochrome P450 2D6 extensive metabolizers. Drug Metab. Dispos. 26:982–988 (1998).
26. M. Gibaldi and D. Perrier. Clearance concepts. In M. Gibaldi and D. Perrier (eds.), Pharmacokinetics, Marcel Dekker, New York, 1982, pp. 319–353.
27. R. Vanholder, N. van Landschoot, R. De-Smet, A. Schoots, and S. Ringoir. Drug protein binding in chronic renal failure: evaluation of nine drugs. Kidney Int. 33:996–1004 (1988).
28. R. Gugler, D. W. Shoeman, D. H. Huffman, J. B. Cohlmia, and D. L. Azarnoff. Pharmacokinetics of drugs in patients with the nephrotic syndrome. J. Clin. Invest. 55:1182–1189 (1975).
29. G. N. Kumar, U. K. Walle, K. N. Bhalla, and T. Walle. Binding of taxol to human plasma, albumin and α1-acid glycoprotein. Res. Commun. Chem. Pathol. Pharmacol. 80:337–344 (1993).
30. H. J. G. D. van den Bongard, E. M. Kemper, O. van Tellingen, H. Rosing, R. A. A. Mathôt, J. H. M. Schellens, and J. H. Beijnen. Development and validation of a method to determine the unbound paclitaxel fraction in human plasma. Anal. Biochem. 324: 11–15 (2004).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jiko, M., Yano, I., Okuda, M. et al. Altered Pharmacokinetics of Paclitaxel in Experimental Hepatic or Renal Failure. Pharm Res 22, 228–234 (2005). https://doi.org/10.1007/s11095-004-1190-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11095-004-1190-6